UroGen Pharma Ltd.
URGN
$16.65
-$0.11-0.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.43% | -32.70% | -24.09% | -9.78% | -4.16% |
| Total Depreciation and Amortization | 14.59% | -17.83% | -30.44% | -24.67% | -17.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.16% | 16.95% | 15.18% | 5.38% | 7.11% |
| Change in Net Operating Assets | 98.14% | 1,127.42% | 47.87% | -29.84% | 767.30% |
| Cash from Operations | -43.55% | -30.07% | -26.70% | -12.93% | -0.39% |
| Capital Expenditure | -65.00% | -98.25% | -52.06% | -56.29% | -17.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -392.24% | -1,024.14% | -2,576.94% | -374.42% | 776.08% |
| Cash from Investing | -399.77% | -1,054.63% | -2,062.96% | -376.36% | 708.48% |
| Total Debt Issued | -- | -- | -- | -2.01% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -92.38% | -20.74% | 122.03% | 120.89% | 8,722.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -61.72% | -61.72% | -61.72% | 420,981.25% |
| Cash from Financing | -85.24% | -18.09% | 66.44% | 36.78% | 893.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -163.45% | -128.61% | 95.04% | -93.53% | 430.03% |